Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Tamoxifen Tablet bulk supplier for pharma manufacturers

Tamoxifen Tablet 10 mg, 20 mg, 40 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 10 mg, 20 mg, 40 mg

Reference Brands: Nolvadex (USA)

Category: Oncology Cancer Care

Tamoxifen tablets (10, 20 mg) are an anti-oestrogen for hormone receptor-positive breast cancer, used after surgery for 5 to 10 years, for advanced disease, and to reduce breast cancer risk in high-risk women. It is on the WHO Essential Medicines List; the original brand is Nolvadex. PharmaTradz sources it for importers, hospitals and tenders, and shares GMP certificates and CoA before you commit.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Tamoxifen Tablet? List it or send an offer →

Product Description:

Tamoxifen is a widely used oncology medication indicated for the treatment and prevention of hormone receptor-positive breast cancer in pre- and postmenopausal women. As a selective estrogen receptor modulator (SERM), it blocks estrogen’s effects in breast tissue, reducing the risk of cancer growth. Tamoxifen is available in 10 mg, 20 mg, and 40 mg oral tablet forms and marketed under brands like Nolvadex® and Soltamox®, as well as multiple generic alternatives in the US and EU. Ideal for pharma B2B buyers, Tamoxifen is manufactured under GMP compliance, ensuring reliable supply for oncology distributors and tender markets.

Tamoxifen Tablet — third party manufacturing & bulk supply

Tamoxifen Tablet 10 mg, 20 mg, 40 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Tamoxifen Tablet is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Tamoxifen Tablet listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Tamoxifen Tablet →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Tamoxifen citrate is used for the treatment and prevention of hormone receptor-positive breast cancer in both pre-menopausal and post-menopausal women and in some cases men. It is also used to reduce the risk of developing breast cancer in high-risk patients.

Tamoxifen is made from the active pharmaceutical ingredient tamoxifen citrate, which is a selective estrogen receptor modulator (SERM) that blocks the effects of estrogen in breast tissue.

Common trade names include Nolvadex and Soltamox.

The original brand Nolvadex was developed by AstraZeneca. Today, Tamoxifen is manufactured by many global pharmaceutical companies as a generic medicine in USA, EU, UK, and other regions.

The generic name is tamoxifen citrate.

Major brand names include Nolvadex and Soltamox, along with multiple regional generic brand versions.

Tamoxifen is manufactured in multiple countries including the USA, UK, EU member states, India, and other regulated pharmaceutical manufacturing regions depending on the marketing authorization holder.

Usually 5 years, and up to 10 years in higher-risk patients.

Strong CYP2D6 inhibitors such as fluoxetine and paroxetine can reduce conversion to its active form endoxifen.

10 mg and 20 mg tablets, and oral solution in some markets.

Related Products

Sorafenib

Strength:
200 mg

Form: Tablet

Reference Brands: Nexavar (US & EU)

View Details
Temozolomide 5 Mg Capsule

Strength:
Capsules: 5 mg, 20 mg, 100 mg, 140 mg; Tablets: 250 mg

Form: Oral Tablets and Oral Capsules

Reference Brands: Temodar® (US & EU)

View Details
Rasburicase

Strength:
1.5 mg/1.5 mL (1.5 mg vial)

Form: Injection

Reference Brands: Elitek® (US & EU)

View Details
Olaparib

Strength:
100 mg, 150 mg

Form: Tablet

Reference Brands: Lynparza® (US & EU)

View Details
Bendamustine Hydrochloride

Strength:
25 mg/vial, 100 mg/vial

Form: Injection (powder for solution)

Reference Brands: Treanda®, Bendeka®(US), Levact®(EU)

View Details
Bortezomib 2 Mg Injection

Strength:
1 mg/vial, 3.5 mg/vial, 2 mg

Form: Injection (lyophilized powder for solution)

Reference Brands: Velcade® (US & EU), Bortecad (India)

View Details
Busulfan

Strength:
Injection: 6 mg/mL; Tablet: 2 mg

Form: Injection (IV), Oral Tablet

Reference Brands: US: Busulfex® (IV), Myleran® (oral); EU: Busilvex® (IV), Myleran® (tablet)

View Details
Cabazitaxel

Strength:
60 mg/1.5 mL

Form: Injection

Reference Brands: Jevtana®(US & EU)

View Details
Enquire Now

Usually answered within 48 hours | GMP documents shared before you commit

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.
WhatsApp us